Drug switch study bolsters case for copies of biotech medicine

LONDON, June 10 (Reuters) - New clinical data has bolstered the case for using cheaper copies of expensive biotech drugs by showing that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a lower-cost version.